home.social

#lundbeck — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #lundbeck, aggregated by home.social.

  1. Lundbeck Reports 2025 Financial Results

    Total revenue increased 13% CER to DKK 24,630 million, supported by US (+21% CER) and Europe (+13% CER) sales. Adjusted EBITDA rose 24% CER. Strategic brands, including Rexulti and Brintellix/Trintellix, grew 19% CER to DKK 19,011 million, accounting for 77% of total revenue.

    #Lundbeck #Biotech #LifeScience #Stocks

  2. Lundbeck Reports 2025 Financial Results

    Total revenue increased 13% CER to DKK 24,630 million, supported by US (+21% CER) and Europe (+13% CER) sales. Adjusted EBITDA rose 24% CER. Strategic brands, including Rexulti and Brintellix/Trintellix, grew 19% CER to DKK 19,011 million, accounting for 77% of total revenue.

    #Lundbeck #Biotech #LifeScience #Stocks

  3. Lundbeck Reports 2025 Financial Results

    Total revenue increased 13% CER to DKK 24,630 million, supported by US (+21% CER) and Europe (+13% CER) sales. Adjusted EBITDA rose 24% CER. Strategic brands, including Rexulti and Brintellix/Trintellix, grew 19% CER to DKK 19,011 million, accounting for 77% of total revenue.

    #Lundbeck #Biotech #LifeScience #Stocks

  4. Lundbeck Reports 2025 Financial Results

    Total revenue increased 13% CER to DKK 24,630 million, supported by US (+21% CER) and Europe (+13% CER) sales. Adjusted EBITDA rose 24% CER. Strategic brands, including Rexulti and Brintellix/Trintellix, grew 19% CER to DKK 19,011 million, accounting for 77% of total revenue.

    #Lundbeck #Biotech #LifeScience #Stocks

  5. Lundbeck Reports 2025 Financial Results

    Total revenue increased 13% CER to DKK 24,630 million, supported by US (+21% CER) and Europe (+13% CER) sales. Adjusted EBITDA rose 24% CER. Strategic brands, including Rexulti and Brintellix/Trintellix, grew 19% CER to DKK 19,011 million, accounting for 77% of total revenue.

    #Lundbeck #Biotech #LifeScience #Stocks

  6. Diabetes tech: a catalyst rich sector with a dazzling future — Lundbeck replaces retiring CEO Deborah Dunsire with UCB exec after breaking sales record --Sanofi's $1.1B eczema drug hits midphase goal, spurring talk of phase 3 and new indications -- See more on our front page news bit.ly/w28kSd #diabetes #medtech #ada #lundbeck #pharmaceos #sanofi #eczema #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  7. Diabetes tech: a catalyst rich sector with a dazzling future — Lundbeck replaces retiring CEO Deborah Dunsire with UCB exec after breaking sales record --Sanofi's $1.1B eczema drug hits midphase goal, spurring talk of phase 3 and new indications -- See more on our front page news bit.ly/w28kSd #diabetes #medtech #ada #lundbeck #pharmaceos #sanofi #eczema #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma